Xenon Pharmaceuticals is a pre-revenue clinical-stage biotech with a promising pipeline but a rapidly accelerating cash burn. R&D expenses grew 124% from $44.2M in 2024Q1 to $99.2M in 2026Q2, driving operating losses to -$123.2M in 2026Q2. The company's cash p...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$1.11+2.6% vs -$1.14 | — vs $2M |
Q2 2026 May 7, 2026 | -$1.17+0.0% vs -$1.17 | — vs $1M |
Q1 2026 Feb 26, 2026 | -$1.31-9.2% vs -$1.20 | — vs $178,571 |
Q4 2025 Nov 3, 2025 | -$1.15+0.9% vs -$1.16 | — vs — |
VANCOUVER, BC and BOSTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference:
VANCOUVER, BC and BOSTON, MA, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to five new non-officer employees consisting of an aggregate of 13,450 share options and 7,850 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company's Board of Directors with an effective date of August 27, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
VANCOUVER, BC and BOSTON, MA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced multiple data presentations at the upcoming 16th European Epilepsy Congress (EEC), taking place September 5-9, 2026, in Athens, Greece.
BlackRock Inc. bought a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ: XENE) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 7,522,482 shares of the biopharmaceutical company's stock, valued at approximately $454,057,000. BlackRock Inc. owned about 7.78% of Xenon Pharmaceuticals
Benchmark XENE against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Xenon Pharmaceuticals Inc. (XENE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $39.09 | $3.78B | -8.97 | — | -4612.13% | -51.76% | — | |
| $300.65 | $8.38B | -22.30 | -100% | — | -34.15% | — | |
| $26.41 | $4.52B | 11.53 | 11.87% | 33.42% | 32.39% | — | |
| $65.96 | $5.47B | 8.48 | 114.51% | -3.8% | — | — | |
| $8.51 | $549.08M | -6.65 | -0.3% | 2.94% | 1.91% | — | |
| $2.76 | $515.13M | -11.50 | 1181.27% | -2178.9% | -23.64% | — |
Xenon Pharmaceuticals Inc. (XENE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Xenon Pharmaceuticals Inc. (XENE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
May 7, 2026·SEC
Apr 13, 2026·SEC
Get notified when XENE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Xenon Pharmaceuticals Inc. (XENE) stock FAQ — growth, dividends, profitability & financials explained
Xenon Pharmaceuticals Inc. (XENE) reported $7.5M in revenue for fiscal year 2025. This represents a 48% decrease from $14.3M in 2012.
Xenon Pharmaceuticals Inc. (XENE) reported a net loss of $409.2M for fiscal year 2025.
Xenon Pharmaceuticals Inc. (XENE) has a return on equity (ROE) of -51.8%. Negative ROE indicates the company is unprofitable.
Xenon Pharmaceuticals Inc. (XENE) had negative free cash flow of $427.6M in fiscal year 2025, likely due to heavy capital investments.
